Aberdeen Group’s Avalyn Pharma AVLN Stock Holding History

Aberdeen Group’s Portfolio AVLN Stock Details AVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-67,174	Closed	-$2.21M	–	1064
2026 Q2	$2.21M	Buy	+67,174	New	+$1.94M	﹤0.01%	766

Other funds holding AVLN

Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Lewis Asset Management Lafayette, California $294M AUM 25.62% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Aberdeen Group's AVLN Position: Q3 2026 in Review

Aberdeen Group sold out of Avalyn Pharma (AVLN) in Q3 2026, closing a stake of 67,174 shares — an estimated $2.21M sold.

Aberdeen Group first reported a position in AVLN in Q2 2026 and held it in 1 quarter. The position peaked at $2.21M in Q2 2026. 23 funds tracked by Wall St. Rank hold AVLN as of Q3 2026.

Aberdeen Group reported no remaining Avalyn Pharma position as of Q3 2026 after selling out during the quarter.
Aberdeen Group sold 67,174 Avalyn Pharma shares in Q3 2026, an estimated $2.21M.
Aberdeen Group first reported a position in Avalyn Pharma in Q2 2026 and held it in 1 quarter.
Aberdeen Group's Avalyn Pharma position peaked at $2.21M in Q2 2026.
23 funds tracked by Wall St. Rank held Avalyn Pharma as of Q3 2026.

Based on Aberdeen Group's 13F filing for Q3 2026, filed 6 Nov 2026.